Apogenix GmbH

A phase 2 clinical trial of a FasL inhibitor, asunercept, showed faster recovery and reduced mortality in severe COVID-19 patients, with an average recovery time of 8 days vs. 13 days in the control group, and a 20% reduction in mortality. The study, published in eClinicalMedicine, suggests the approach could be effective for other respiratory RNA viruses.